Abstract
Hematopoietic cell transplantation (HCT) is potentially curative for patients with sickle cell disease (SCD). Both SCD and HCT cause kidney damage. This study analyzed data from 160 patients who received nonmyelablative HCT for SCD. Renal function was assessed at baseline and annually for 3years. The rate of new-onset eGFR <60 ml/min/1.73m2 was low (2.8%). Rapid kidney function decline in the first year post-HCT was noted in 7.5% of patients but was not associated with subsequently worse renal function. The eGFR decreased post-HCT (1 year: –7.19 p < 0.0001, 2 year: –11.32 *p* < 0.0001, 3 year: -12.37 ml/min/1.73m2 p < 0.0001). Mean eGFR remained within normal limits throughout the follow-up period (1 year:119, 2 year:115, 3 year:113 ml/min/1.73m2). Hyperfiltration rates decreased with a corresponding increase in patients with normal eGFR post-HCT. Therefore, the decline in eGFR after HCT may represent preservation of renal function. The prevalence of kidney damage increased transiently but, by 3 years post-HCT, was not significantly changed from baseline. Most cases of kidney damage were due to albuminuria. AKI, noted early post-HCT in 39% of patients, was most commonly stage 1 and was associated with decreased survival (p = 0.03). Larger studies with longer follow-up are required to explore the effects of HCT on renal function in patients with SCD.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Change institution
Buy or subscribe
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: Schematic of patients included in baseline and 1, 2, and 3-year post-HCT analyses.
Fig. 2: Slope of eGFR decline post-transplant.
Fig. 3: Trend of eGFR post-HCT shown by mean values with 95% confidence intervals.
Fig. 4
Fig. 5: The proportion of patients at each time point with kidney damage defined by UACR ≥ 30 mg/dL and/or eGFR <60 mL/min/1.73 m2.
Fig. 6: A lower baseline eGFR is seen in patients who developed AKI and remains lower throughout the follow-up period.
Fig. 7: Kaplan Meier curve demonstrating differences in survival up to 10 years after HCT between patients with and without AKI.
Data availability
The datasets analysed in this study are available from the corresponding author on reasonable request.
References
Ataga KI, Saraf SL, Derebail VK. The nephropathy of sickle cell trait and sickle cell disease. Nat Rev Nephrol. 2022;18:361–77.
PubMedPubMed CentralGoogle Scholar
Saraf SL, Zhang X, Kanias T, Lash JP, Molokie RE, Oza B, et al. Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Br J Haematol. 2014;164:729–39.
CASPubMedGoogle Scholar
Yeruva SL, Paul Y, Oneal P, Nouraie M. Renal failure in sickle cell disease: prevalence, predictors of disease, mortality and effect on length of hospital stay. Hemoglobin. 2016;40:295–9.
CASPubMedPubMed CentralGoogle Scholar
Olaniran KO, Allegretti AS, Zhao SH, Nigwekar SU, Kalim S. Acute kidney injury among black patients with sickle cell trait and sickle cell disease. Clin J Am Soc Nephrol. 2021;16:348–55.
CASPubMedPubMed CentralGoogle Scholar
Powars D, Chan L, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Hemoglobin. 2005;84:363–76.
Google Scholar
Sharpe C, Thein S. Sickle cell nephropathy - a practical approach. Br J Haematol. 2011;155:287–97.
CASPubMedGoogle Scholar
Airy M, Eknoyan G. The kidney in sickle hemoglobinopathies. Clin Nephrol. 2017;87:55–68.
PubMedGoogle Scholar
Elmariah H, Garrett M, De Castro L, Jonassaint J, Ataga K, Eckman J, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89:530–5.
CASPubMedPubMed CentralGoogle Scholar
Powars D, Elliott-Mills D, Chan L, Niland J, Hiti A, Opas L, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med. 1991;115:614–20.
CASPubMedGoogle Scholar
Zahr RS, Ataga KI, Lebensburger JD, Winer JC. Kidney failure outcomes in children and young adults with sickle cell disease in the United States Renal Data System. Pediatr Nephrol. 2024;39:619–23.
PubMedGoogle Scholar
Saddadi F, Hakemi M, Najafi I, Moghadam K, Ghavamzadeh A, Jahani M, et al. Chronic kidney disease after hematopoietic cell transplantation: frequency, risk factors, and outcomes. Transpl Proc. 2009;41:2895–7.
CASGoogle Scholar
Ellis MJ, Parikh CR, Inrig JK, Kanbay M, Patel UD. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transpl. 2008;8:2378–90.
CASGoogle Scholar
Touzot M, Elie C, van Massenhove J, Maillard N, Buzyn A, Fakhouri F. Long-term renal function after allogenic haematopoietic stem cell transplantation in adult patients: a single-centre study. Nephrol Dialysis Transpl. 2010;25:624–7.
Google Scholar
Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508.
CASPubMedGoogle Scholar
Hingorani S, Pao E, Stevenson P, Schoch G, Laskin BL, Gooley T, et al. Changes in glomerular filtration rate and impact on long-term survival among adults after hematopoietic cell transplantation: a prospective cohort study. Clin J Am Soc Nephrol. 2018;13:866–73.
PubMedPubMed CentralGoogle Scholar
Hingorani SR, Seidel K, Lindner A, Aneja T, Schoch G, McDonald G. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transpl. 2008;14:1365–72.
Google Scholar
Kersting S, Verdonck L. Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction. Biol Blood Marrow Transpl. 2008;14:1312–6.
Google Scholar
Zager RA, O’Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1989;13:210–6.
CASPubMedGoogle Scholar
Kanduri SR, Cheungpasitporn W, Thongprayoon C, Bathini T, Kovvuru K, Garla V, et al. Incidence and mortality of acute kidney injury in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. QJM. 2020;113:621–32.
CASPubMedPubMed CentralGoogle Scholar
Pedersen SJV, Monagel DA, Mammen C, Lewis VA, Guilcher GMT, Bruce AA. Stable renal function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2020;67:e28568.
CASPubMedGoogle Scholar
Krishnamurti L, Kharbanda S, Biernacki MA, Zhang W, Baker KS, Wagner JE, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transpl. 2008;14:1270–8.
Google Scholar
Matthes-Martin S, Lawitschka A, Fritsch G, Lion T, Grimm B, Breuer S, et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol. 2013;90:308–12.
PubMedGoogle Scholar
Dallas MH, Triplett B, Shook DR, Hartford C, Srinivasan A, Laver J, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transpl. 2013;19:820–30.
Google Scholar
Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79:268–88.e1.
PubMedGoogle Scholar
Selistre L, Rabilloud M, Cochat P, de Souza V, Iwaz J, Lemoine S, et al. Comparison of the Schwartz and CKD-EPI equations for estimating glomerular filtration rate in children, adolescents, and adults: a retrospective cross-sectional study. PLoS Med. 2016;13:e1001979.
PubMedPubMed CentralGoogle Scholar
Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821–35.
PubMedGoogle Scholar
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2012;158:825–30.
Google Scholar
Ephraim R. Chronic kidney disease is common in sickle cell disease: a cross-sectional study in the Tema Metropolis, Ghana. BMC Nephrol. 2015;16:75.
PubMedPubMed CentralGoogle Scholar
KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements [Internet]. 2012; 2. Available from: https://kdigo.org/guidelines/acute-kidney-injury/.
Derebail V, Ciccone E, Zhou Q, Kilgore R, Cai J, Ataga K. Progressive Decline in Estimated GFR in Patients with Sickle Cell Disease: An Observational Cohort Study. Am J Kidney Dis. 2019;74:47–55.
PubMedPubMed CentralGoogle Scholar
Dovern E, Aydin M, DeBaun MR, Alizade K, Biemond BJ, Nur E. Effect of allogeneic hematopoietic stem cell transplantation on sickle cell disease-related organ complications: a systematic review and meta-analysis. Am J Hematol. 2024;99:1129–41.
CASPubMedGoogle Scholar
Lebensburger JD, Derebail VK. Sickle cell disease and the kidney. Filters Gone Awry Hematol Oncol Clin North Am 2022;36:1239–54.
PubMedGoogle Scholar
Hoste E, Clermont G, Kersten A, Venkataraman R, Angus D, De Bacquer D, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically Ill patients: a cohort analysis. Crit Care. 2006;10:R73.
PubMedPubMed CentralGoogle Scholar
Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med. 2006;34:1913–7.
PubMedGoogle Scholar
Renaghan AD, Jaimes EA, Malyszko J, Perazella MA, Sprangers B, Rosner MH. Acute kidney injury and CKD associated with hematopoietic stem cell transplantation. Clin J Am Soc Nephrol. 2020;15:289–97.
CASPubMedGoogle Scholar
Fitzhugh CD, Volanakis EJ, Idassi O, Duberman JA, DeBaun MR, Friedman DL. Long-term health effects of curative therapies on heart, lungs, and kidneys for individuals with sickle cell disease compared to those with hematologic malignancies. J Clin Med. 2022;11:3118.
CASPubMedPubMed CentralGoogle Scholar
Asnani M, Reid M. Cystatin C: a useful marker of glomerulopathy in sickle cell disease? Blood Cells Mol Dis. 2015;54:65–70.
CASPubMedGoogle Scholar
Yee M, Lane P, Archer D, Joiner C, Eckman J, Guasch A. Estimation of glomeruloar filtration rate using serum cystatin C and creatinine in adults with sickle cell anemia. Am J Hematol. 2017;92:E598–E9.
CASPubMedGoogle Scholar
Alvarez O, Zilleruelo G, Wright D, Montane B, Lopez-Mitnik G. Serum cystatin C levels in children with sickle cell disease. Pediatr Nephrol. 2006;21:533–7.
PubMedGoogle Scholar
Barreto M, Limerick E, Jeffries N, Varga J, Gharib A, Clark M, et al. Creatinine-based estimating equations for GFR outperform cystatin C-based equations in adults with sickle cell disease. Foundation for Sickle Cell Research; Fort Lauderdale, FL (2023).
Download references
Acknowledgements
Drs. Delbert Wigfall and Annabelle Chua of Duke Medical Center for contributing pediatric nephrology expertise.
Funding
This research was funded by the Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE, 1U01HL156620-01, National Heart, Lung, and Blood Institute (NHLBI)) and was supported by the intramural research program of the NHLBI, National Institutes of Health.
Author information
Author notes
These authors contributed equally: Santosh L. Saraf, Courtney D. Fitzhugh.
Authors and Affiliations
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Emily Limerick, Matthew M. Hsieh, Mauricio Barretto, Neal Jeffries, Ritika Menon & Courtney D. Fitzhugh
Department of Medicine, Department of Nephrology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
Clarissa Diamantidis
Division of Biostatistics, Duke University School of Medicine, Durham, NC, USA
Yuliya Lokhnygina
Division of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, IL, USA
Santosh L. Saraf
Authors
Emily Limerick
View author publications
You can also search for this author inPubMedGoogle Scholar
2. Matthew M. Hsieh
View author publications
You can also search for this author inPubMedGoogle Scholar
3. Mauricio Barretto
View author publications
You can also search for this author inPubMedGoogle Scholar
4. Neal Jeffries
View author publications
You can also search for this author inPubMedGoogle Scholar
5. Clarissa Diamantidis
View author publications
You can also search for this author inPubMedGoogle Scholar
6. Yuliya Lokhnygina
View author publications
You can also search for this author inPubMedGoogle Scholar
7. Ritika Menon
View author publications
You can also search for this author inPubMedGoogle Scholar
8. Santosh L. Saraf
View author publications
You can also search for this author inPubMedGoogle Scholar
9. Courtney D. Fitzhugh
View author publications
You can also search for this author inPubMedGoogle Scholar
Contributions
EL, CD, YL, SS, and CF conceived and designed the analyses; EL, MH, and SS collected data; MB and RM contributed data; EL and NJ performed the analyses, EL and CF drafted the manuscript. All authors reviewed and approved the final manuscript.
Corresponding authors
Correspondence to Santosh L. Saraf or Courtney D. Fitzhugh.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All methods were performed in accordance with the relevant guidelines and regulations. Approval has been obtained from the National Institutes of Health and University of Illinois Chicago institutional review boards. Informed consent was obtained from all participants.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplemental Materials
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Limerick, E., Hsieh, M.M., Barretto, M. et al. Kidney function after nonmyeloablative hematopoietic cell transplant for sickle cell disease. Bone Marrow Transplant (2025). https://doi.org/10.1038/s41409-025-02550-0
Download citation
Received:21 July 2024
Revised:17 January 2025
Accepted:11 March 2025
Published:22 March 2025
DOI:https://doi.org/10.1038/s41409-025-02550-0
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative